Molecular mechanisms of impaired antigenic presentation as a cause of tumor escape from immune surveillance

Close metadata

Recommended articles:

Pathomorphological criteria and features of immune response in eosinophilic esophagitis and reflux esophagitis. Russian Journal of Archive of Pathology. 2024;(1):5-12

Claudin-18.2 and gastric cancer: from physiology to carcinogenesis. Russian Journal of Archive of Pathology. 2024;(6):92-99

Uncontrolled inhibition of checkpoints. P.A. Herzen Journal of Oncology. 2024;(2):67-73

Modern treatment methods for patients with liver metastases from uveal melanoma. P.A. Herzen Journal of Oncology. 2024;(2):74-84

Regulatory miRNA21, miRNA92, miRNA221 and miRNAlet7 expression in carotid and coronary atherosclerotic plaques. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(3):245-252

CPG oligonucleotides as vaccine adjuvants for prevention of infectious diseases. Molecular Genetics, Microbiology and Virology. 2024;(3):3-11

Immune checkpoint inhibitors as a component of perioperative therapy in patients with resectable esophageal and cardioesophageal junction cancer. P.A. Herzen Journal of Oncology. 2024;(5):62-68

Local cytokine profile of the endometrium in patients with repeated implantation failures and its pharmacological correction by the secretome of peripheral blood mononuclear cells. Russian Journal of Human Reproduction. 2024;(5):46-54

Antigen receptors in the development of CAR-T cells for glioblastoma immunotherapy. P.A. Herzen Journal of Oncology. 2024;(6):91-95

Possibilities of using bacterial lysates in the treatment and prevention of upper respiratory tract infectious diseases. Russian Rhinology. 2024;(4):314-322

The review summarizes data on the features of antigen presentation in tumor cells. The molecular mechanisms of the antitumor immune response are considered with an emphasis on the ability of tumor cells to avoid the action of immune surveillance. The features of expression of MHC molecules depending on treatment regimens are provided. Ways to improve existing and create new treatment regimens aimed at elimination of tumor cells because of antitumor immune response are discussed.

Keywords:

immunotherapy

antigen

major histocompatibility complex

expression

immune response

Authors:

Korotaeva A.A.

Research Centre for Medical Genetics

ORCID: 0000-0003-0083-3005

Borunova A.A.

N.N. Blokhin National Medical Research Center of Oncology

ORCID: 0000-0001-5874-5804

Kuzevanova A.Yu.

Research Centre for Medical Genetics

ORCID: 0000-0001-6156-9725

Zabotina T.N.

N.N. Blokhin National Medical Research Center of Oncology

ORCID: 0000-0001-7631-5699

Alimov A.A.

Research Centre for Medical Genetics

ORCID: 0000-0002-8495-7728

Received:

25.08.2023

Accepted:

20.09.2023

List of references:

Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol. 2019;37(28):2518-2527. https://doi.org/10.1200/JCO.19.00934
Goodman AM, Castro A, Pyke RM, Okamura R, Kato S, Riviere P, Frampton G, Sokol E, Zhang X, Ball ED, et al. MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Med. 2020;12(1):45. https://doi.org/10.1186/s13073-020-00743-4
Shklovskaya E, Lee JH, Lim SY, Stewart A, Pedersen B, Ferguson P, Saw RP, Thompson JF, Shivalingam B, Carlino MS, et al. Tumor MHC expression guides first-line immunotherapy selection in melanoma. Cancers (Basel). 2020;12(11):3374. https://doi.org/10.3390/cancers12113374
Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol. 2021;12:636568. https://doi.org/10.3389/fimmu.2021.636568
Cornel AM, Mimpen IL, Nierkens S. MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers (Basel). 2020;12(7):1760. https://doi.org/10.3390/cancers12071760
Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Ma R, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol. 2020;15(10):1636-1646. https://doi.org/10.1016/j.jtho.2020.07.014
Antonelli AC, Binyamin A, Hohl TM, Glickman MS, Redelman-Sidi G. Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling. Proc Natl Acad Sci USA. 2020;117(31):18627-18637. https://doi.org/10.1073/pnas.2004421117
Marofi F, Al-Awad AS, Sulaiman Rahman H, Markov A, Abdelbasset WK, Ivanovna Enina Y, Mahmoodi M, Hassanzadeh A, Yazdanifar M, Stanley Chartrand M, et al. CAR-NK cell: a new paradigm in tumor immunotherapy. Front Oncol. 2021;11:673276. https://doi.org/10.3389/fonc.2021.673276
Liu Y, Wang Y, Yang Y, Weng L, Wu Q, Zhang J, Zhao P, Fang L, Shi Y, Wang P. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct Target Ther. 2023;8(1):104. https://doi.org/10.1038/s41392-023-01365-z
Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol. 2018;19(1):76-84. https://doi.org/10.1038/s41590-017-0004-z
Wang Y, Yin C, Feng L, Wang C, Sheng G. Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro. Genet Mol Res. 2015;14(2):5630-5641. https://doi.org/10.4238/2015.May.25.15
Lasorsa F, di Meo NA, Rutigliano M, Milella M, Ferro M, Pandolfo SD, Crocetto F, Tataru OS, Autorino R, Battaglia M, et al. Immune checkpoint inhibitors in renal cell carcinoma: molecular basis and rationale for their use in clinical practice. Biomedicines. 2023;11(4):1071. https://doi.org/10.3390/biomedicines11041071
Kwiecień I, Rutkowska E, Raniszewska A, Sokołowski R, Bednarek J, Jahnz-Różyk K, Rzepecki P, Domagała-Kulawik J. Immunosuppressive properties of human PD-1+ , PDL-1+ and CD80 + dendritic cells from lymph nodes aspirates of lung cancer patients. Cancer Immunol Immunother. 2022;71(10):2469-2483. https://doi.org/10.1007/s00262-022-03178-5
Trowsdale J. Genomic structure and function in the MHC. Trends Genet. 1993;9(4):117-122. https://doi.org/10.1016/0168-9525(93)90205-V
Paul S, Weiskopf D, Angelo MA, Sidney J, Peters B, Sette A. HLA class I alleles are associated with peptide-binding repertoires of different size, affinity and immunogenicity. J Immunol. 2013;191(12):5831-5839. https://doi.org/10.4049/jimmunol.1302101
León-Letelier RA, Katayama H, Hanash S. Mining the immunopeptidome for antigenic peptides in cancer. Cancers (Basel). 2022;14(20):4968. https://doi.org/10.3390/cancers14204968
Shklovskaya E, Rizos H. MHC class I deficiency in solid tumors and therapeutic strategies to overcome it. Int J Mol Sci. 2021;22(13):6741. https://doi.org/10.3390/ijms22136741
Muntjewerff EM, Meesters LD, van den Bogaart G, Revelo NH. Reverse signaling by MHC-I molecules in immune and non-immune cell types. Front Immunol. 2020;11:605958. https://doi.org/10.3389/fimmu.2020.605958
Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582. https://doi.org/10.1038/ncomms10582
Hu Q, Bian Q, Rong D, Wang L, Song J, Huang HS, Zeng J, Mei J, Wang PY. JAK/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens. Front Bioeng Biotechnol. 2023;11:1110765. https://doi.org/10.3389/fbioe.2023.1110765
Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother. 2008;57(2):197-206. https://doi.org/10.1007/s00262-007-0362-8
Cabrera T, Angustias Fernandez M, Sierra A, Garrido A, Herruzo A, Escobedo A, Fabra A, Garrido F. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol. 1996;50(2):127-134. https://doi.org/10.1016/0198-8859(96)00145-0
Menon AG, Morreau H, Tollenaar RA, Alphenaar E, Van Puijenbroek M, Putter H, Janssen-Van Rhijn CM, Van De Velde CJ, Fleuren GJ, Kuppen PJ. Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab Invest. 2002;82(12):1725-1733. https://doi.org/10.1097/01.lab.0000043124.75633.ed
Park HS, Cho U, Im SY, Yoo CY, Jung JH, Suh YJ, Choi HJ. Loss of human leukocyte antigen class I expression is associated with poor prognosis in patients with advanced breast cancer. J Pathol Transl Med. 2019;53(2):75-85. https://doi.org/10.4132/jptm.2018.10.11
Kurdi M, Alshareef A, Bamaga AK, Fadel ZT, Alrawaili MS, Hakamy S, Mohamed F, Abuzinadah AR, Addas BMJ, Butt NS. The assessment of major histocompatibility complex (MHC) class-I expression in different neuromuscular diseases. Degener Neurol Neuromuscul Dis. 2021;11:61-68. https://doi.org/10.2147/DNND.S340117
Meissner TB, Li A, Biswas A, Lee KH, Liu YJ, Bayir E, Iliopoulos D, van den Elsen PJ, Kobayashi KS. NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc Natl Acad Sci USA. 2010;107(31):13794-13799. https://doi.org/10.1073/pnas.1008684107
Kelly A, Trowsdale J. Genetics of antigen processing and presentation. Immunogenetics. 2019;71(3):161-170. https://doi.org/10.1007/s00251-018-1082-2
Rodríguez T, Méndez R, Del Campo A, Jiménez P, Aptsiauri N, Garrido F, Ruiz-Cabello F. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer. 2007;7:34. https://doi.org/10.1186/1471-2407-7-34
Lorenzi S, Forloni M, Cifaldi L, Antonucci C, Citti A, Boldrini R, Pezzullo M, Castellano A, Russo V, van der Bruggen P, et al. IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma. PLoS One. 2012;7(10):e46928. https://doi.org/10.1371/journal.pone.0046928
Shi AH, Ho LL, Levine S, Yadav V, Cheah J, Soule C, Frederick DT, Liu D, Boland G, Kellis M. Abstract 948: Epigenomic correlates of checkpoint blockade immunotherapy resistance. Cancer Res. 2019;79(13 suppl.):948. https://doi.org/10.1158/1538-7445.AM2019-948
Blander JM. Regulation of the cell biology of antigen cross-presentation. Annu Rev Immunol. 2018;36:717-753. https://doi.org/10.1146/annurev-immunol-041015-055523
Ritz U, Seliger B. The transporter associated with antigen processing (TAP): structural integrity, expression, function, and its clinical relevance. Mol Med. 2001;7(3):149-158. https://doi.org/10.1007/BF03401948
Ling A, Löfgren-Burström A, Larsson P, Li X, Wikberg ML, Öberg Å, Stenling R, Edin S, Palmqvist R. TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer. Oncoimmunology. 20177;6(11):e1356143. https://doi.org/10.1080/2162402X.2017.1356143
Taylor BC, Balko JM. Mechanisms of MHC-I downregulation and role in immunotherapy response. Front Immunol. 2022;13:844866. https://doi.org/10.3389/fimmu.2022.844866
Henle AM, Nassar A, Puglisi-Knutson D, Youssef B, Knutson KL. Downregulation of TAP1 and TAP2 in early stage breast cancer. PloS One. 2017;12(11):e0187323. https://doi.org/10.1371/journal.pone.0187323
Li X, Zeng S, Ding Y, Nie Y, Yang M. Comprehensive analysis of the potential immune-related biomarker transporter associated with antigen processing 1 that inhibits metastasis and invasion of ovarian cancer cells. Front Mol Biosci. 2021;8:763958. https://doi.org/10.3389/fmolb.2021.763958
Wang ZD, Tian X, Wang Y, Wang JJ, Ye SQ, Huang YQ, Qu YY, Chang K, Shi GH, Ye DW, et al. The expression and prognostic value of transporter 1, ATP binding cassette subfamily B member in clear cell renal cell cancer with experimental validation. Front Oncol. 2022;12:1013790. https://doi.org/10.3389/fonc.2022.1013790
Compagnone M, Cifaldi L, Fruci D. Regulation of ERAP1 and ERAP2 genes and their disfunction in human cancer. Hum Immunol. 2019;80(5):318-324. https://doi.org/10.1016/j.humimm.2019.02.014
Hammer GE, Gonzalez F, James E, Nolla H, Shastri N. In the absence of aminopeptidase ERAAP, C class I molecules present many unstable and highly immunogenic peptides. Nat Immunol. 2007;8(1):101-108. https://doi.org/10.1038/ni1409
Koumantou D, Barnea E, Martin-Esteban A, Maben Z, Papakyriakou A, Mpakali A, Kokkala P, Pratsinis H, Georgiadis D, Stern LJ, et al. Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1). Cancer Immunol Immunother. 2019;68(8):1245-1261. https://doi.org/10.1007/s00262-019-02358-0
Garrido G, Schrand B, Rabasa A, Levay A, D’Eramo F, Berezhnoy A, Modi S, Gefen T, Marijt K, Doorduijn E, et al. Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity. Nat Commun. 2019;10(1):3773. https://doi.org/10.1038/s41467-019-11728-2
Nagasaki J, Togashi Y, Sugawara T, Itami M, Yamauchi N, Yuda J, Sugano M, Ohara Y, Minami Y, Nakamae H, et al. The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma. Blood Adv. 2020;4(17):4069-4082. https://doi.org/10.1182/bloodadvances.2020002098
Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, et al. Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell. 2020;181(7):1612-1625.e13. https://doi.org/10.1016/j.cell.2020.05.017
Sacher AG, St Paul M, Paige CJ, Ohashi PS. Cytotoxic CD4+ T cells in bladder cancer — a new license to kill. Cancer Cell. 2020; 38(1):28-30. https://doi.org/10.1016/j.ccell.2020.06.013
Gonzalez-Ericsson PI, Wulfkhule JD, Gallagher RI, Sun X, Axelrod ML, Sheng Q, Luo N, Gomez H, Sanchez V, Sanders M, et al. Tumor-specific major histocompatibility-II expression predicts benefit to anti-PD-1/L1 therapy in patients with HER2-negative primary breast cancer. Clin Cancer Res. 2021;27(19):5299-5306. https://doi.org/10.1158/1078-0432.CCR-21-0607
Rodig SJ, Gusenleitner D, Jackson DG, Gjini E, Giobbie-Hurder A, Jin C, Chang H, Lovitch SB, Horak C, Weber JS, et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. 2018;10(450):eaar3342. https://doi.org/10.1126/scitranslmed.aar3342
Yi R, Hong S, Zhang Y, Lin A, Ying H, Zou W, Wang Q, Wei T, Cheng Q, Zhu W, et al. MHC-II signature correlates with anti-tumor immunity and predicts anti-PD-L1 response of bladder cancer. Front Cell Dev Biol. 2022;10:757137. https://doi.org/10.3389/fcell.2022.757137
Algarra I, Garrido F, Garcia-Lora AM. MHC heterogeneity and response of metastases to immunotherapy. Cancer Metastasis Rev. 2021;40(2):501-517. https://doi.org/10.1007/s10555-021-09964-4
Yoshihama S, Cho SX, Yeung J, Pan X, Lizee G, Konganti K, Johnson VE, Kobayashi KS. NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy. Sci Rep. 2021;11(1):3258. https://doi.org/10.1038/s41598-021-82729-9
Lee JH, Shklovskaya E, Lim SY, Carlino MS, Menzies AM, Stewart A, Pedersen B, Irvine M, Alavi S, Yang JY, et al. Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nat Commun. 2020;11(1):1897. https://doi.org/10.1038/s41467-020-15726-7
Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F, Salim M, Vallon-Christersson J, Törngren T, Kvist A, et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun. 2017;8(1):1738. https://doi.org/10.1038/s41467-017-01460-0
Khallouf H, Märten A, Serba S, Teichgräber V, Büchler MW, Jäger D, Schmidt J. 5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I. J Immunother. 2012;35(3):245-253. https://doi.org/10.1097/CJI.0b013e31824b3a76
Wan S, Pestka S, Jubin RG, Lyu YL, Tsai YC, Liu LF. Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PLoS One. 2012;7(3):e32542. https://doi.org/10.1371/journal.pone.0032542
Iwai T, Sugimoto M, Wakita D, Yorozu K, Kurasawa M, Yamamoto K. Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies. Oncotarget. 2018;9(59):31411-31421. https://doi.org/10.18632/oncotarget.25830
Alagkiozidis I, Facciabene A, Tsiatas M, Carpenito C, Benencia F, Adams S, Jonak Z, June CH, Powell DJ Jr, Coukos G. Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. J Transl Med. 2011;9:77. https://doi.org/10.1186/1479-5876-9-77
Tu J, Xu H, Ma L, Li C, Qin W, Chen X, Yi M, Sun L, Liu B, Yuan X. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells. Theranostics. 2022;12(2):747-766. https://doi.org/10.7150/thno.65828
Tsai AK, Khan AY, Worgo CE, Wang LL, Liang Y, Davila E. A multikinase and DNA-PK inhibitor combination immunomodulates melanomas, suppresses tumor progression, and enhances immunotherapies. Cancer Immunol Res. 2017;5(9):790-803. https://doi.org/10.1158/2326-6066.CIR-17-0009
Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin Lymphoma. J Clin Oncol. 2018;36(10):942-950. https://doi.org/10.1200/JCO.2017.77.3994

Close metadata